Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

OPC-28326

😃Good
Catalog No. T13804Cas No. 167626-17-7

OPC-28326 is a specific an α2-adrenergic receptor antagonist and acts as a peripheral vasodilator. OPC-28326 inhibits α2A-, α2B- and α2C-adrenoceptors with Ki of 2040, 285, and 55 nM, respectively.

OPC-28326

OPC-28326

😃Good
Purity: 99.79%
Catalog No. T13804Cas No. 167626-17-7
OPC-28326 is a specific an α2-adrenergic receptor antagonist and acts as a peripheral vasodilator. OPC-28326 inhibits α2A-, α2B- and α2C-adrenoceptors with Ki of 2040, 285, and 55 nM, respectively.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$197In StockIn Stock
5 mg$479In StockIn Stock
10 mg$653In StockIn Stock
25 mg$990In StockIn Stock
50 mg$1,330In StockIn Stock
100 mg$1,750-In Stock
200 mg$2,370-In Stock
1 mL x 10 mM (in DMSO)$597In StockIn Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products. If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.79%
Appearance:Solid
Color:Yellow
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
OPC-28326 is a specific an α2-adrenergic receptor antagonist and acts as a peripheral vasodilator. OPC-28326 inhibits α2A-, α2B- and α2C-adrenoceptors with Ki of 2040, 285, and 55 nM, respectively.
Targets&IC50
α2A-adrenoceptor:2040 nM (ki), α2C-adrenoceptor:55 nM (ki), α2B-adrenoceptor:285 nM (ki)
In vitro
OPC-28326 augments microvessel growth and improves endothelial tube formation. OPC-28326 dose-dependently induces phosphorylation of eNOS and Akt without affecting total amounts of eNOS and Akt in HAECs[1].
In vivo
OPC-28326 improves blood flow recovery in murine hindlimb ischemia and increases the number of capillaries in the ischemic leg[1]. In rats, intravenous administration of OPC-28326 (3 - 30 mg/kg) and yohimbine (0.3 - 3 mg/kg) results in a dose-dependent rightward shift in the pressor dose-response curve induced by B-HT 920 without affecting the mydriasis[2].
Chemical Properties
Molecular Weight421.58
FormulaC26H35N3O2
Cas No.167626-17-7
SmilesC(=O)(C1=CC(C)=C(NC(CC)=O)C(C)=C1)N2CCC(N(CCC3=CC=CC=C3)C)CC2
Relative Density.1.13 g/cm3 (Predicted)
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 4.22 mg/mL (10.01 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.3720 mL11.8601 mL23.7203 mL118.6015 mL
5 mM0.4744 mL2.3720 mL4.7441 mL23.7203 mL
10 mM0.2372 mL1.1860 mL2.3720 mL11.8601 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy OPC-28326 | purchase OPC-28326 | OPC-28326 cost | order OPC-28326 | OPC-28326 chemical structure | OPC-28326 in vivo | OPC-28326 in vitro | OPC-28326 formula | OPC-28326 molecular weight